Lowest Price Guaranteed
Slides
236
Last Updated
June 2025
View Count
9474
The global digital PCR market size, valued at USD 8.42 billion in 2024, is projected to reach USD 9.39 billion in 2025 and USD 23.15 billion by 2035, representing a CAGR of 9.4% during the forecast period.
 |
Digital PCR (dPCR) is a groundbreaking technique that helps in the quantification of targeted molecules, even at low concentration. This technology is highly beneficial in detecting DNA traces, genetic mutations and copy number variation. Digital PCR leverages the same fundamental chemistry as quantitative PCR, but the data is collected in dPCR at the endpoint of the reaction mix.
Over the years, traditional PCR technologies (such as real-time PCR and quantitative PCR) have been used for molecular diagnostics / quantification of targeted molecules. However, the inability to detect low-abundance genetic mutations and rare targets in cancer and other diseases has necessitated the demand for digital PCR. This technology offers high sensitivity, precision and absolute quantification of small gene expression levels, making it a valuable tool for disease diagnosis at molecular level and biomarker detection.
The demand for digital PCR has been further spurred by the rising prevalence of viral diseases (SARS COVID-19, Zika virus, Oropouche virus, and Marburg virus) across the world. It is important to highlight here that according to the World Healthcare Organization, around 11,634 cases of Oropouche virus and two deaths has been reported in the America in 2024, posing a risk of high death ratio in the upcoming years. Notably, digital PCR has become a third-generation technology that facilitates early disease diagnosis, biomarkers detection, gene mutation identification and quantify rare targets that further facilitate the development of precision medicine.
This emerging technology has caught the attention of industrial players to take strategic initiatives for the development of advanced digital PCR solutions. Market players, such as Thermos Fisher Scientific, Bio-Rad and QIAGEN are focusing on product development and advanced software that aid in quantification and analysis of low concentrated molecules.
For instance, in January 2025, QIAGEN expanded its capability of QIAcuity digital PCR system wherein there is a two-fold increase in the number of targets under analysis. As stated by Nitin Sood (Senior Vice President and Head of the Life Sciences Business Area, QIAGEN), “Analyzing more targets simultaneously from a single biological sample is an important step in making QIAcuity even more the top choice for groundbreaking dPCR applications. We are exploring ways to further increase the capabilities of QIAcuity to help researchers gain a deeper biological understanding of any sample type in a cost-efficient way without tedious optimization or fear of inaccurate quantification.“
Notably, this system was launched in September 2024, making it a valuable addition to its digital PCR portfolio for the usage across clinical diagnostics with higher precision. Earlier, in April 2024, Bio-Rad Laboratories announced a collaboration agreement with Oncocyte (precision diagnostics company) for the development and commercialization of transplant monitoring products using Droplet Digital™ PCR (ddPCR™) instruments and reagents of Bio-Rad Laboratories.
Driven by the ongoing digital PCR technology launch and rising adoption for early diagnosis, we believe that digital PCR market is likely to remain competitive and investible for long term.
The market report provides comprehensive information on digital PCR companies who are currently active across various segments of the industry as mentioned in the table below.
| Key Report Attributes | Details | |
| Historical Trend | Since 2020 | |
| Forecast Period | Till 2035 | |
| Current Market Size | USD 9.39 Billion | |
| Market Size 2035 | USD 23.15 Billion | |
| CAGR (Till 2035) | 9.4% | |
| Type of Offering |
|
|
| Type of Technology |
|
|
| Type of Offering |
|
|
| Type of Indication |
|
|
| Type of Application Area |
|
|
| End User |
|
|
| Geographical Regions |
|
|
| Key Digital PCR Companies Profiled |
|
|
| PowerPoint Presentation (Complimentary) |
Available | |
| Customization Scope | 15% Free Customization | |
| Excel Data Packs (Complimentary) |
Available | |
One of the key objectives of digital PCR market report was to estimate the current size, opportunity and the market growth potential, over the forecast period, till 2035. We have provided informed estimates on the likely evolution of the market for the forecast period.
The market analysis report also features the likely distribution of the current and forecasted opportunity within the market across various segments, such as type of PCR (droplet digital PCR, chip-based digital PCR, and BEAMing digital PCR), type of technology (quantitative, digital and end-point) type of offering instruments, reagents & consumables, and software and services, type of indication (infectious diseases, oncology, genetic disorders, and other indications), type of application area (clinical, research and forensic), end-user (hospital & clinics, pharmaceutical & biotechnology industries, clinical laboratories, and academic & research organizations), geographical region (North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America) and leading players.
In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of industry’s evolution.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. The financial figures mentioned in this market report are in USD, unless otherwise specified.
The global market is categorized based on the type of PCR into droplet digital PCR, chip-based digital PCR, and BEAMing digital PCR. According to our market analysis, droplet digital PCR occupies the highest share (over 80%) of the market. This is likely to be the result of high quantification efficiency by using low volume of sample and reagent which significantly reduced the cost of overall sample analysis.
However, it is important to note that chip-based segment is likely to grow at a higher CAGR during the forecast period. This can be attributed to its ability of partitioning samples into thousands of tiny droplets on a chip. This chip-based digital PCR allows more accurate quantification of targeted molecules and rare targets. Additionally, chip-based digital PCR ensures miniaturization.
Interestingly, there has been a growing interest among the key players in expanding their dPCR product portfolio. In June 2024, Roche Diagnostics Korea launched Digital LightCycler, the first dPCR device in the country based on chip-based technology. As stated by Kit Tang (CEO, Roche Diagnostics),” Digital PCR technology offers exceptional sensitivity, allowing for early diagnosis of genetic cancer diseases and detection of residual cancer cells post-treatment. This capability provides new opportunities for predicting treatment efficacy and recurrence risks.”
This segment highlights the distribution of global market across different types of technology, such as quantitative, digital and end-point. Currently, quantitative PCR technology accounts for the highest digital PCR market share. This can be attributed to the fact that quantitative PCR technology utilizes fluorescent dues and calibration curves which deliver quantitative data within real time. This real-time analysis helps in faster interpretation of data, making it a valuable tool in disease diagnosis. However, in the future it is estimated that digital technology will gain momentum at a higher CAGR during the forecast period.
Based on the type of offering, the global market is distributed into instruments, reagents & consumables, and software and services. Currently, reagents & consumables segment accounts for the highest digital PCR market share (over 60%) driven by the rising demand for digital PCR reagents & consumables for quantitative analysis of molecules. Furthermore, the increasing adoption of digital diagnostics kits has necessitated the demand for reagents & consumables, which further contributed to the highest share of this segment.
However, in the long run, instruments, and software and services segment are likely to grow at a higher CAGR during the forecast period. This can be attributed to the growing integration of software and adoption of instruments for advanced analysis and exploring its more applications.
The global digital PCR market size is further split based on the type of indication into infectious diseases, oncology, genetic disorders, and other indications. According to our market analysis, currently genetic disorders account for the largest share of the market. This can be attributed to the high specificity and sensitivity of dPCR in the detection of gene alteration / expression. Furthermore, the co-relation of gene mutation and expression with diseases has bolstered the demand for digital PCR for rare gene targets to develop personalized treatment.
However, in the long run, oncology segment is likely to grow at a higher CAGR during the forecast period. This can be expected to be the result of expanding usage of digital PCR for cancer biomarker detection, early diagnosis and understanding can prognosis. It is important to highlight here that infectious diseases also hold a substantial share of the market.
On the basis of application area, the global market is segmented into clinical, research and forensic. Currently, clinical segment accounts for the highest market share (over 35%). This can be attributed to the growing adoption of digital PCR technology in hospitals and clinical diagnostics laboratories for early disease diagnosis.
According to our digital PCR market forecast, in the long run, research segment is likely to grow at a higher CAGR during the forecast period. This is likely to be the result of expanding usage across academic research for research studies and drug development.
Based on the end user, the global market is distributed into hospital & clinics, pharmaceutical & biotechnology industries, clinical laboratories, and academic & research organizations. Among these, presently, academic & research organizations account for the highest digital PCR market share (nearly 35%). This can be attributed to the expanding adoption of digital PCRs for quantitative studies in real-time by academic researchers. It is worth noting that digital PCRs play a significant role in research studies across various applications, such as oncology, genetic disease and other research areas, which is anticipated to expand its usage in academic & research organizations.
However, during the forecast period clinical laboratories and pharmaceutical & biotechnology industries segments are expected to drive at a higher CAGR. This is primarily due to the increasing usage of digital PCR tools and technologies for drug development, target identification and biomarker identification. Whereas in clinical laboratories, it helps to detect disease at early stage which further helps healthcare practitioners in providing optimal treatment to patients at right time.
Currently, North America is dominating industry by holding nearly 45% of overall revenue of the global market. This can be attributed to the growing acceptance of advanced digital technologies, rising prevalence of cancer and increasing expenditure on healthcare infrastructure to improve patient outcomes.
However, in Asia-Pacific, the market for digital PCR is anticipated to grow at a higher CAGR during the forecast period. This is likely to be the result of growing incidence of infectious diseases and rising adoption of advanced diagnostic technologies to early and accurate diagnosis.
In 2024, Global Clinical Central Lab (GCCL), a company based in Korea, launched droplet dPCR in the domestic clinical trial sample analysis industry. This innovation is likely to support the analysis of cell and gene therapy clinical trials, ultimately leading to better success for CGT drug development.
The “Digital PCR Market: Industry Trends and Global Forecasts, till 2035” research report features an extensive study of the focus on competitive landscape of strategic initiatives, emerging mega trends, big pharma initiatives, company profiles and key drivers and restraints. The market report highlights the efforts of several stakeholders engaged in this rapidly evolving segment of life sciences industry. Key takeaways of the market report are briefly discussed below.
Currently, the landscape of digital PCR companies is immensely competitive, featuring wide array of well-established and new-entrants. Notably, these industrial players are consistently driving research and development activities to offer innovative digital PCR platforms and technologies with automation, high sensitivity and scalability.
However, the primary focus is on automation and integration of artificial intelligence to enhance real-time studies which is one of the evolving requirements of researchers. In order to leverage the competitive edge, several industrial players are entering into partnerships and collaborations for the development of cutting-edge digital PCR technologies.
For instance, in September 2024, Stilla Technologies (dPCR solution provider) entered into a strategic partnership with Niba Labs (leading digital PCR assay developer for gene therapy). The partnership will emphasize the development of innovative digital PCR assays that are customized to the requirement of the gene therapy industry. As more market players continue to focus on technological innovations, we believe this market will remain competitive during the forecast period.
Several growth factors that are anticipated to propel the market include rising incidence of infectious and cancer diseases that demand advanced diagnostic solutions for disease diagnosis. Furthermore, continuous innovation in digital PCR technology such as high throughput and increased sensitivity for precise quantification of nucleic acids is likely to be a key driver for the market.
In addition, the growth demand for personalized medicine for the treatment of wide range of disease indications, specifically cancer and genetic disorders has bolstered the demand for advanced digital PCR technologies. Notably, digital PCR offers high level of accuracy which is achieved by partitioning samples into thousands of separate reactions. This accuracy is highly required in quantification of unparallel nucleic acids and detection of rare genetic mutations, ensuring high reliability on test results. Therefore, the high reliability of digital PCR has catered the attention of healthcare professionals for early disease diagnosis, which is likely to be a key growth factor.
Despite high demand, the market for digital PCR is witnessing several challenges that need to be addressed. Some of the notable challenges in digital PCR market are high cost and technological complexities. Notably, digital PCR systems and consumables are expensive and require regular maintenance, which limits its adoption across various industrial verticals.
Additionally, technology requires specialized equipment and skilled personnel for operation, which seems like a significant barrier for widespread adoption of this dPCR. Moreover, the availability of inexpensive or alternative diagnostic tools such as next-generation sequencing, CRISPR-based diagnostics that offer high throughput and capability of detecting gene defects poses a competition in the market.
There is an expanding application of digital PCR technology such as increasing usage for gene expression analysis, liquid biopsy, and pathogen detection. It is important to highlight here that the growing demand for liquid biopsies for early cancer detection has underscored the requirement for digital PCR technologies. Notably, digital PCR’s sensitivity allows the detection of mutated genes or nucleic acids (even at low concentration), making it an essential tool for liquid biopsy assays.
Moreover, the growing technological advancements, such as multiplexing for the analysis of multiple gene targets simultaneously and improved sensitivity in the digital PCR technology for rare mutation detection are offering enormous opportunities to industrial players for innovations in this field. Additionally, microfluidic advancements and integration of digital PCR with other technologies for comprehensive analysis of targeted genes are the key growth trends in the market.
The global digital PCR market is estimated to be valued at USD 9.39 billion in 2025 and is poised to reach USD 23.15 billion by 2035, representing a higher CAGR of 9.4% during the forecast period. The market is primarily driven by the increasing demand for high throughput and sensitivity for early disease detection, specifically cancer and infectious disorders.
In order to drive the development of advanced digital PCR technologies several industrial players are taking strategic initiatives followed by collaboration and partnerships. For instance, in September 2024, Seegene announced an extension of its strategic partnership with Springer Nature to launch “Nature Award MDx Impact Grants” project to develop advanced diagnostic assays using Seegene’s advanced multiplex PCR technology.
Examples of key digital PCR companies (which have also been captured in this report) include Agilent Technologies, BioMerieux, Bio-Rad Laboratories, BD, Danaher, Eppendorf, Fluidigm, Formulatrix, Illumina, JN Medsys, LGC Biosearch Technologies, Merck, Precigenome, Promega, PerkinElmer, QIAGEN, Quantabio, Roche, Stilla Technologies, Sysmex, Thermo Fisher Scientific and Takara Bio. This market report includes an easily searchable excel database of all the companies focusing on digital PCR technologies and solutions.
The market report presents an in-depth analysis, highlighting the capabilities of various companies engaged in this domain across different segments. Amongst other elements, the market report includes:
Several recent developments have taken place in the digital PCR field. We have outlined some of these recent initiatives below.